| Document |
Document Title |
|
WO/2018/221526A1 |
[Problem] To provide a high-calorie nutritional composition having good flavor and stable physical properties. [Solution] A nutritional composition comprises a protein source. The protein source of the nutritional composition includes wh...
|
|
WO/2018/221654A1 |
The invention provides citrulline or a salt thereof and glutathione or a salt thereof for use in increasing a ratio of muscle mass to total body weight in a person in conjunction with a resistance workout program, as well as a method of ...
|
|
WO/2018/216818A1 |
[Problem] To obtain a muscle quality improvement agent that is administered orally to a human or animal individual and that is able to cause qualitative change of muscle fibers of an individual administered to. [Solution] Provided is a m...
|
|
WO/2018/213340A1 |
Provided are a recombinant acid α-glucosidase and pharmaceutical composition comprising a recombinant acid α-glucosidase, wherein the recombinant acid α-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an in...
|
|
WO/2018/211425A1 |
A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration ...
|
|
WO/2018/213715A1 |
Provided herein are methods and compositions related to treating and/or preventing sleep disorders and for improving sleep health in a subject by administering to the subject (e.g., orally administering to the subject) a composition comp...
|
|
WO/2018/211510A1 |
Methods of treating an aging-associated disease, as well as inhibiting aging in a subject, by administering pharmaceutical compositions comprising unmodified and modified MSCs and their exosomes are provided.
|
|
WO/2018/211498A1 |
Methods of treating progressive forms of multiple sclerosis are provided, comprising administering adipose-derived stem cells into the central nervous system (CNS). Further provided are improved methods for obtaining ADSCs, which are mor...
|
|
WO/2018/207918A1 |
Provided is a method for easily and highly efficiently purifying and concentrating mesenchymal stem cells (MSC). More specifically, mesenchymal stem cells (MSC) can be easily and highly efficiently purified and concentrated by separating...
|
|
WO/2018/207741A1 |
The purpose of the present invention is to provide drugs which are capable of promoting the biosynthesis of PGC-1α participating in energy production or inhibiting slow-to-fast muscle conversion caused by, for example, lack of exercise,...
|
|
WO/2018/204617A1 |
The present invention relates generally to stable liquid formulations comprising polypeptides with 10Fn3 domains which bind to myostatin and unit dosage forms thereof for administration various routes, including subcutaneous (SC), for tr...
|
|
WO/2018/203559A1 |
Provided are: pharmaceutical compositions for polyglutamine diseases and the uses thereof; methods for prevention, amelioration, progress-suppression and/or treatment of polyglutamine diseases using such pharmaceutical compositions; and ...
|
|
WO/2018/197708A1 |
The invention relates to 20-hydroxyecdysone and the derivatives thereof, for use in the treatment of genetic myopathies.
|
|
WO/2018/197731A1 |
The invention concerns a method for preparing an extract from a preparation of approximately 90% pure 20-hydroxyecdysone that comprises the following steps: g) Hot dissolution of approximately 90% pure 20-hydroxyecdysone in methanol, fil...
|
|
WO/2018/199166A1 |
The purpose of the present invention is to provide: compounds having a TrkA inhibiting effect, or pharmacologically acceptable salts thereof, or solvates of these; pharmaceutical compositions characterized by containing these as an activ...
|
|
WO/2018/199109A1 |
Provided is a therapeutic agent, a preventive agent, or the like that is for diseases caused by accumulation of abnormal protein and that contains a compound represented by general formula (I) (in the formula, R1 and R2 each represent a ...
|
|
WO/2018/200605A1 |
Provided herein are methods for treating levodopa-induced dyskinesia by administering to a subject (,S)-2-amino-3 -methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9, 10-dimethoxy- 1,3,4,6,7,11b-hexahydro-2H-pyrido[2,l-a]isoquinolin-2-yl este...
|
|
WO/2018/195046A1 |
The present disclosure provides a method for stimulating asymmetric division of at least some satellite stem cells in a patient suffering from a disease or disorder characterized by satellite cells having an inability, or a reduced abili...
|
|
WO/2018/189208A1 |
The present invention concerns the use of antisense oligonucleotides (AON) capable of inhibiting expression of dynamin 2, advantageously human dynamin 2, for use in the treatment of Charcot-Marie-Tooth disease (CMT) and centronuclear myo...
|
|
WO/2018/151841A9 |
Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are method...
|
|
WO/2018/187493A1 |
Compositions and methods for fetal or in utero delivery of active agents are provided. The compositions are most typically administered intravenously via the vitelline vein, umbilical vein, or directly into the amniotic cavity of a pregn...
|
|
WO/2018/187209A1 |
In certain aspects, the disclosure provides compositions and methods for treating spinal muscular atrophy. For example, in some embodiments, the disclosure provides ALK4:ActRIIB antagonists that may be used to treat spinal muscular atrop...
|
|
WO/2018/186480A1 |
The inventors of the present invention found that an HMGB1 peptide fragment having a specific amino acid sequence is effective at suppressing finger fusion and scarring of the digestive tract, and at prolonging survival in malnutrition- ...
|
|
WO/2018/186365A1 |
The present invention relates to a novel read-through inducing agent, and also relates to a compound represented by general formula (I) (symbols in the formula are as described in the specification) or a pharmaceutically accepted salt th...
|
|
WO/2018/177244A1 |
An shRNA expression cassette, a polynucleotide sequence carrying the expression cassette, and an application thereof. The shRNA expression cassette contains, in order from 5' to 3', a DNA sequence expressing the shRNA and a filler sequen...
|
|
WO/2018/178029A1 |
The present invention relates to a method for treating degenerative muscular and/or neurological conditions or diseases. The inventors found that SIRT3 is decreased with age in human striated muscles which are post-mitotic cells. More pa...
|
|
WO/2018/178237A1 |
The invention relates to a method for treating mitochondrial genetic diseases. The inventors have worked with primary fibroblasts from patients and control individuals and collected protein lysates for western blotting. Importantly, they...
|
|
WO/2018/181345A1 |
Provided is a compound which has an Nrf2-activating activity and is expected to be useful as a prophylactic or therapeutic agent for diseases associated with oxidative stress, particularly hepatitis (e.g., non-alcoholic steatohepatitis (...
|
|
WO/2018/178030A1 |
The present invention relates to a method for treating degenerative muscular and/or neurological conditions or diseases. The inventors found that TRF2 is decreased with age in human striated muscles which are post-mitotic cells. More par...
|
|
WO/2018/177893A1 |
Tyrosine kinase inhibitors, selected from nintedanib and pharmaceutically acceptable salts thereof, can be used in methods for the treatment of muscular dystrophy.
|
|
WO/2018/170794A1 |
An ALS model, a method for screening a medicament for treating ALS and a method for constructing ALS model, wherein the ALS model expresses mutant FUS and the mutant FUS is FUS-R521C.
|
|
WO/2018/170796A1 |
Provided is a pharmaceutical composition comprising a scavenger, wherein the scavenger is used for clearing away mutant FUS. A method for treating or preventing or alleviating ALS is also provided.
|
|
WO/2018/173986A1 |
[Problem] To provide granules (a granular product) containing an amino acid which can regulate the bitterness of the amino acid, are highly meltable in the mouth and have excellent taste and properties, and a method for stably manufactur...
|
|
WO/2018/173653A1 |
The present invention addresses the problem of providing an autophagy-inducing agent which comprises, as an active ingredient, a highly-safe natural material having a remarkable autophagy-inducing effect and which can be administered to ...
|
|
WO/2018/170335A1 |
The present disclosure provides distinct therapeutic populations of cells that form a pharmaceutical composition useful in hematopoietic stem/progenitor cell transplant. For example, the present disclosure provides a therapeutic populati...
|
|
WO/2018/169804A1 |
A neuromuscular toxin is for use in treating abnormalities of the first metatarsophalangeal joint of the foot of a mammal by administering an amount of neuromuscular toxin effective to treat the abnormalities via intramuscular injection ...
|
|
WO/2018/164251A1 |
The present invention addresses the problem of providing a novel composition for improving physical strength. According to the present invention, a composition for improving physical strength which contains milk protein as an active ingr...
|
|
WO/2018/162617A1 |
The present invention relates to AceFaPC (1-Acetyl-2-Fatty acyl-glyceroPhosphoCholine) for use in the prevention and treatment of diseases associated with an acetylcholine deficiency. The invention also relates to the AceFaPC molecule in...
|
|
WO/2018/164221A1 |
The purpose of the present invention is to provide: a composition for inhibiting myofibrosis, which contains, as an active ingredient, a component that can be safely ingested over a prolonged period of time; and a method for safely inhib...
|
|
WO/2018/162931A1 |
The present invention provides a method for determining whether a patient will respond to treatment with a myostatin pathway inhibitor, the method comprising : (a) determining a level of myostatin and/or activin type II receptor (ActRII)...
|
|
WO/2018/157258A1 |
A method of improving at least one of the following in an individual: lean mass, muscle strength, cognition, systemic inflammation levels, blood cholesterol levels, blood triglyceride levels and glucose tolerance is provided, comprising ...
|
|
WO/2018/159852A1 |
The purpose of the present invention is to provide a curcumin-containing solid composition which can be used as a composition for treatment or prevention of disorders or symptoms in which intracellular absorption of curcumin is beneficia...
|
|
WO/2018/154412A1 |
The present application provides materials and methods for treating a patient with one or more conditions or disorders associated with LAMA2, both ex vivo or in vivo. For example, the present disclosure provides materials and methods for...
|
|
WO/2018/157009A1 |
The invention related to polynucleotides comprising an open reading frame of linked nucleosides encoding therapeutic proteins or variant therapeutic proteins, isoforms thereof, functional fragments thereof, and fusion proteins comprising...
|
|
WO/2018/154578A1 |
Compounds represented by general Formulae I to IV as described herein are disclosed. Further disclosed are composition utilizing the herein disclosed compounds and using the same for the treatment of glycogen storage disorders.
|
|
WO/2018/151225A1 |
The muscle differentiation promoter according to the present invention includes oligo DNA having activity to promote muscle differentiation by being applied to cells or to an individual. The oligo DNA preferably includes a core base sequ...
|
|
WO/2018/144677A1 |
Disclosed herein are methods of reducing muscle contraction in a diaphragm or peripheral muscle(s) of a patient sufficient to permit a surgical procedure. The methods may comprise the step of administering an oxime or pharmaceutically ac...
|
|
WO/2018/137483A1 |
A sustained-release nanoparticle for targeting a neurodegenerative disease, a preparation method thereof, a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing and/or treating a neurodegen...
|
|
WO/2018/140412A1 |
The present invention describes the use of a 5HT3-antagonist, in combination with neostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis or other myasthenic syndromes by providing a therapeutically effecti...
|
|
WO/2018/138646A1 |
The present invention relates to a fusion peptide comprising an active peptide portion and a carrier peptide portion. The present invention further relates to the use of such peptide as medicament, particularly for use in the prevention,...
|
